Sarah joined Juvena Therapeutics as a Senior Research Associate to contribute to Dr. Fengling Liu’s research on protein expression and purification. She obtained her bachelor’s degree in molecular and cell biology from the University of California, Berkeley.
Before joining Juvena Therapeutics, Sarah worked as a Research Associate in the antibody discovery field, where she attained hybridoma sequences, antibody transient expression, and hit identification. Prior to transitioning to research, Sarah worked in the clinical diagnostics field as a Lab Administrative Manager. She managed lab operations while staying active on the bench.
In Sarah’s free time, she enjoys creating content for her cat’s social media, gaming with friends, and attending ballet performances.
Annie joined Juvena Therapeutics as a research associate II working on preclinical in vivo and in vitro disease modeling and drug discovery.
She received her master’s degree in Biomedical Engineering from the University of Southern California. During her time as a graduate student, Annie participated as a research volunteer in an immunology group. Her project focused on investigating the influence of the coronavirus envelope protein on CD1d expression. This experience provided her with valuable training in fundamental molecular techniques, such as genotyping, flow cytometry, western blotting, and conducting in vivo experiments.
Before joining Juvena, Annie worked as a Research Associate in the field of toxicology at Sorrento Therapeutics for one year. In this position, she played a crucial role in supporting the toxicity team, particularly in the tissue cross-reactivity assay. Her responsibilities included performing histological procedures such as embedding and sectioning both paraffin and frozen tissues, conducting H&E staining, IHC, IF, and acquiring images.
During her free time, Annie finds joy in activities such as jogging, hiking, and gaming with her friends.
Dr. Molineaux has been the Chief Executive Officer at Para Therapeutics, Inc., since April 2023. Previously, she was Chief Executive Officer, President and a member of the board of directors of Calithera Biosciences, Inc., since co-founding the company in June 2010 until March 2023. Dr. Molineaux has served as a member of the board of directors of the Geron Corporation since 2012, Repare Therapeutics since April 2023, Cyteir Therapeutics, Inc., a clinical-stage DNA repair and synthetic lethality company, from December 2020 until May 2023, and Theravance Biopharma, Inc., a biopharmaceutical company, from April 2015 to April 2022. She has also been a Scientific Advisor to Lightstone Ventures, a private life sciences investment company, since September 2016. Dr. Molineaux co-founded Proteolix, Inc., a privately held oncology-oriented biopharmaceutical company, where she served as Chief Scientific Officer from December 2003 until December 2005 and from February 2009 until November 2009, and as President and Chief Executive Officer from January 2006 until February 2009, until the company’s acquisition by Onyx Pharmaceuticals, Inc., a global oncology-oriented biopharmaceutical company, in November 2009.
Previously, Dr. Molineaux held several senior management positions in the biopharmaceutical industry, including Vice President of Biology at Rigel Pharmaceuticals, Inc., a biopharmaceutical company focused on inflammatory and autoimmune diseases, Vice President of Biology at Praelux, Inc., a biopharmaceutical company, and Vice President of Drug Development at Praecis Pharmaceuticals, Inc., an oncology-focused biopharmaceutical company. Dr. Molineaux holds a B.S. in biology from Smith College, a Ph.D. in molecular biology from Johns Hopkins University and completed a postdoctoral fellowship at Columbia University.
Theodore Yu joined Juvena Therapeutics as a research associate contributing to protein production and in-vitro assay development. Theodore earned his undergraduate degree in biology, with a minor in chemistry, from San Jose State University. During his time at SJSU, he served as an undergraduate research assistant in the Payumo Lab, focused on cardiac regenerative biology. Theodore’s role investigated molecular and cellular processes regulating cardiomyocyte cell cycle regulation, through molecular cloning techniques and IHC staining. Outside of work, Ted enjoys spending time with his family, friends, and cat. He also finds joy in taking scenic drives through the hills.
Dr. Louis Aronne is a leading authority on obesity and its treatment. He is the Sanford I. Weill Professor of Metabolic Research and the director of the Comprehensive Weight Control Center in the division of Endocrinology, Diabetes & Metabolism at Weill Cornell Medicine in New York City. A graduate of Johns Hopkins University School of Medicine, Dr. Aronne is a founder and past chairman of the American Board of Obesity Medicine and a past president of The Obesity Society. He is a founder and Executive Chairman of Intellihealth, a cloud-based weight management system for healthcare providers.
He completed his internship and residency at Albert Einstein College of Medicine and Jacobi Medical Center, followed by a Henry J. Kaiser Family Foundation Fellowship in General Internal Medicine at New York-Presbyterian/Weill Cornell Medical Center.
Dr Lingvay is an active member of the American Diabetes Association, where she has served over the years on several committees, including the Organizing Committee for the Annual Scientific Sessions, Focus on Fellows Advisory Board, WIN-ADA Advisory Board, Grant Review Committee, and the Professional Practice Committee. She is on the Editorial Board of several journals, including Diabetes Care. She participated in nearly 100 clinical trials and has a special interest in cardiovascular outcome trials and obesity trials. She authored over 160 publications in major medical journals and authored chapters in several popular diabetes textbooks.
Dr. Ildiko Lingvay is a Tenured Professor of Medicine in the Division of Endocrinology and Professor in the Peter O’Donnell Jr. School of Public Health at UT Southwestern Medical Center. Dr. Lingvay is the Medical Director of the Office of Clinical Trials Management, overseeing the institutional approval of all clinical trials at UT Southwestern. She is Board Certified both in Obesity Medicine as well as Endocrinology, Diabetes and Metabolism.
Dr Lingvay leads a program that focuses on clinical research in the field of obesity and type 2 diabetes. Her research interests span the spectrum from pathophysiology of the disease to treatment algorithms and comparative effectiveness of various therapeutic approaches. Dr Lingvay treats patients at the UT Southwestern clinics and hospitals as well as the Parkland Health & Hospital System.
Dr Lingvay is an active member of the American Diabetes Association, where she has served over the years on several committees, including the Organizing Committee for the Annual Scientific Sessions, Focus on Fellows Advisory Board, WIN-ADA Advisory Board, Grant Review Committee, and the Professional Practice Committee. She is on the Editorial Board of several journals, including Diabetes Care. She participated in nearly 100 clinical trials and has a special interest in cardiovascular outcome trials and obesity trials. She authored over 160 publications in major medical journals and authored chapters in several popular diabetes textbooks.
CEO Dr. Hanadie Yousef is interviewed by Ira Pastor for his Progress, Potential, and Possibilities show on Juvena’s development of Secretome Derived Therapies
Dr. Hannoush is a general partner at Mubadala Capital, the financial investment arm of the Sovereign Wealth Fund Mubadala. He focuses on early-stage biotechnology investments, and also leads the firm’s efforts in life sciences company creation. Prior to his current position, Dr. Hannoush spent fifteen years at Genentech where he was a Senior Group Leader, and he led both early- and late-stage discovery biology programs in Ophthalmology, Immunology and Oncology, with a focus on drug discovery and development, as well as target discovery and validation.
His former Laboratory in translational biology at Genentech focused on new drug modalities and understanding the role of protein – protein interactions in stem cell signaling pathways for cellular reprogramming and tissue regeneration, and his group made important contributions in the fields of Wnt signaling and protein lipidation. He obtained his PhD in Chemistry from McGill University and did his postdoctoral training in chemical biology and cell biology at Harvard.
